EML4-ALK融合基因异形及其相关耐药性的研究进展  

Research Advances in EML4-ALK Fusion Variants and Its Related Drug Resistance

作　　者：隋泽森 张建华 SUI Zesen;ZHANG Jianhua(Department of Thoracic Surgery,Shenzhen Hospital of Southern Medical University,Shenzhen 518110,China)

机构地区：[1]南方医科大学深圳医院胸外科,广东深圳518110

出　　处：《医学综述》2020年第12期2318-2322,共5页Medical Recapitulate

基　　金：深圳市宝安区医疗卫生科研项目(2016CX309)。

摘　　要：肺癌的发病率及病死率较高,以年轻非吸烟女性易患为特点,其中肺腺癌占非小细胞肺癌的50%以上。由棘皮动物微管相关蛋白样4(EML4)和间变淋巴瘤激酶(ALK)融合成的EML4-ALK是肺腺癌最具有特点的致癌基因。随着对分子学认识的加深,目前发现了约17种EML4-ALK融合异形,不同的融合异形具有不同的分子结构,结构的差异决定着融合异形的作用,目前关于不同融合异形是否会影响分子靶向药物疗效的研究较少,且结论尚不统一。Lung cancer still ranks the first place in terms of morbidity and mortality of all cancers.Lung adenocarcinoma,characterized by young age onset,large number of female patients and susceptible to non-smoking patients,has been occupying more than 50%of non-small cell lung cancer.EML4-ALK which is fused from echinoderm microtubule-associated protein-like 4(EML4)and anaplastic lymphoma kinase(ALK),is the most characteristic oncogene in lung adenocarcinoma.With the deepening of molecular research,about 17 kinds of EML4-ALK fusion variants have been found,and different variants have different molecular structures,which determines the role of variants.At present,studies on whether different fusion variants affect the efficacy of molecular targeted drugs are insufficient,and the conclusions are not unified.

关 键 词：棘皮动物微管相关蛋白4-间变淋巴瘤激酶 融合基因异形 耐药性 克唑替尼 肺癌 

分 类 号：R734.2[医药卫生—肿瘤]